Leiner Asks FDA About Restarting U.S. OTC Operations, Posts $27.5 Mil. Loss
This article was originally published in The Tan Sheet
Executive Summary
Heightened concerns over product quality triggered by adulterated Chinese imports and the need for more than one U.S. private-label supplier are fueling Leiner Health Products' optimism as it prepares to reenter the OTC market and recover from setbacks that led to a $27.5 million net loss in its latest quarter, CEO Robert Kaminski said Aug. 14
You may also be interested in...
Leiner Teetered Toward Bankruptcy As FDA Investigated Testing Fraud
Whistleblowers' allegations of stability data manipulation at Leiner Health Products prompted the firm's rapid fall from a leading provider of private-label OTC drugs and dietary supplements to a property bought by a competitor in a bankruptcy court auction
Leiner Teetered Toward Bankruptcy As FDA Investigated Testing Fraud
Whistleblowers' allegations of stability data manipulation at Leiner Health Products prompted the firm's rapid fall from a leading provider of private-label OTC drugs and dietary supplements to a property bought by a competitor in a bankruptcy court auction
Leiner Teetered Toward Bankruptcy As FDA Investigated Testing Fraud
Whistleblowers' allegations of stability data manipulation at Leiner Health Products prompted the firm's rapid fall from a leading provider of private-label OTC drugs and dietary supplements to a property bought by a competitor in a bankruptcy court auction